HEPA
Price
$0.66
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
JAGX
Price
$1.13
Change
-$0.00 (-0.00%)
Updated
Oct 28 closing price
Ad is loading...

HEPA vs JAGX

Header iconHEPA vs JAGX Comparison
Open Charts HEPA vs JAGXBanner chart's image
Hepion Pharmaceuticals
Price$0.66
Change-$0.00 (-0.00%)
Volume$15.76K
CapitalizationN/A
Jaguar Health
Price$1.13
Change-$0.00 (-0.00%)
Volume$162.88K
CapitalizationN/A
View a ticker or compare two or three
HEPA vs JAGX Comparison Chart
Loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
VS
HEPA vs. JAGX commentary
Oct 30, 2024

To compare these two companies we present long-term analysis, their fundamental ratings and make comparative short-term technical analysis which are presented below. The conclusion is HEPA is a Buy and JAGX is a StrongBuy.

COMPARISON
Comparison
Oct 30, 2024
Stock price -- (HEPA: $0.66 vs. JAGX: $1.13)
Brand notoriety: HEPA and JAGX are both not notable
Both companies represent the Biotechnology industry
Current volume relative to the 65-day Moving Average: HEPA: 31% vs. JAGX: 58%
Market capitalization -- HEPA: $3.94M vs. JAGX: $12.57M
HEPA [@Biotechnology] is valued at $3.94M. JAGX’s [@Biotechnology] market capitalization is $12.57M. The market cap for tickers in the [@Biotechnology] industry ranges from $531.34B to $0. The average market capitalization across the [@Biotechnology] industry is $2.92B.

Long-Term Analysis

It is best to consider a long-term outlook for a ticker by using Fundamental Analysis (FA) ratings. The rating of 1 to 100, where 1 is best and 100 is worst, is divided into thirds. The first third (a green rating of 1-33) indicates that the ticker is undervalued; the second third (a grey number between 34 and 66) means that the ticker is valued fairly; and the last third (red number of 67 to 100) reflects that the ticker is undervalued. We use an FA Score to show how many ratings show the ticker to be undervalued (green) or overvalued (red).

HEPA’s FA Score shows that 1 FA rating(s) are green whileJAGX’s FA Score has 1 green FA rating(s).

  • HEPA’s FA Score: 1 green, 4 red.
  • JAGX’s FA Score: 1 green, 4 red.
According to our system of comparison, both HEPA and JAGX are a bad buy in the long-term.

Short-Term Analysis

It is best to consider a short-term outlook for a ticker by using Technical Analysis (TA) indicators. We use Odds of Success as the percentage of outcomes which confirm successful trade signals in the past.

If the Odds of Success (the likelihood of the continuation of a trend) for each indicator are greater than 50%, then the generated signal is confirmed. A green percentage from 90% to 51% indicates that the ticker is in a bullish trend. A red percentage from 90% - 51% indicates that the ticker is in a bearish trend. All grey percentages are below 50% and are considered not to confirm the trend signal.

HEPA’s TA Score shows that 4 TA indicator(s) are bullish while JAGX’s TA Score has 2 bullish TA indicator(s).

  • HEPA’s TA Score: 4 bullish, 5 bearish.
  • JAGX’s TA Score: 2 bullish, 8 bearish.
According to our system of comparison, HEPA is a better buy in the short-term than JAGX.

Price Growth

HEPA (@Biotechnology) experienced а -12.01% price change this week, while JAGX (@Biotechnology) price change was -4.24% for the same time period.

The average weekly price growth across all stocks in the @Biotechnology industry was +0.91%. For the same industry, the average monthly price growth was +2.47%, and the average quarterly price growth was -6.27%.

Reported Earning Dates

HEPA is expected to report earnings on Aug 30, 2023.

JAGX is expected to report earnings on May 19, 2023.

Industries' Descriptions

@Biotechnology (+0.91% weekly)

Biotechnology involves genetic or protein engineering to produce medicines/therapies for treating and preventing ailments. The industry also provides crucial ingredients for diagnostics. This multi-billion-dollar industry is heavily focused on research and development, as companies attempt to continually come up with cutting-edge solutions for health. New discoveries for the treatment of diseases provide opportunities for growth for a company in this industry. Discoveries, however, must pass the regulatory approval from the U.S. Food and Drug Administration (FDA) before they can make it to markets. Amgen Inc., Gilead Sciences, Inc. and Celgene Corporation are examples of companies in this industry.

SUMMARIES
Loading...
FUNDAMENTALS
Fundamentals
JAGX($12.6M) has a higher market cap than HEPA($3.94M). HEPA YTD gains are higher at: -79.630 vs. JAGX (-87.561). JAGX has higher annual earnings (EBITDA): -30.6M vs. HEPA (-35.58M). JAGX has more cash in the bank: 16M vs. HEPA (2.12M). HEPA has less debt than JAGX: HEPA (154K) vs JAGX (34.2M). JAGX has higher revenues than HEPA: JAGX (10.2M) vs HEPA (0).
HEPAJAGXHEPA / JAGX
Capitalization3.94M12.6M31%
EBITDA-35.58M-30.6M116%
Gain YTD-79.630-87.56191%
P/E RatioN/A0.28-
Revenue010.2M-
Total Cash2.12M16M13%
Total Debt154K34.2M0%
FUNDAMENTALS RATINGS
HEPA vs JAGX: Fundamental Ratings
HEPA
JAGX
OUTLOOK RATING
1..100
8268
VALUATION
overvalued / fair valued / undervalued
1..100
31
Undervalued
18
Undervalued
PROFIT vs RISK RATING
1..100
100100
SMR RATING
1..100
99100
PRICE GROWTH RATING
1..100
6565
P/E GROWTH RATING
1..100
10092
SEASONALITY SCORE
1..100
n/a50

Tickeron ratings are formulated such that a rating of 1 designates the most successful stocks in a given industry, while a rating of 100 points to the least successful stocks for that industry.

JAGX's Valuation (18) in the Pharmaceuticals Generic industry is in the same range as HEPA (31) in the null industry. This means that JAGX’s stock grew similarly to HEPA’s over the last 12 months.

JAGX's Profit vs Risk Rating (100) in the Pharmaceuticals Generic industry is in the same range as HEPA (100) in the null industry. This means that JAGX’s stock grew similarly to HEPA’s over the last 12 months.

HEPA's SMR Rating (99) in the null industry is in the same range as JAGX (100) in the Pharmaceuticals Generic industry. This means that HEPA’s stock grew similarly to JAGX’s over the last 12 months.

HEPA's Price Growth Rating (65) in the null industry is in the same range as JAGX (65) in the Pharmaceuticals Generic industry. This means that HEPA’s stock grew similarly to JAGX’s over the last 12 months.

JAGX's P/E Growth Rating (92) in the Pharmaceuticals Generic industry is in the same range as HEPA (100) in the null industry. This means that JAGX’s stock grew similarly to HEPA’s over the last 12 months.

TECHNICAL ANALYSIS
Technical Analysis
HEPAJAGX
RSI
ODDS (%)
Bearish Trend 2 days ago
86%
Bearish Trend 2 days ago
90%
Stochastic
ODDS (%)
Bullish Trend 2 days ago
80%
Bullish Trend 2 days ago
80%
Momentum
ODDS (%)
Bullish Trend 2 days ago
82%
Bearish Trend 2 days ago
90%
MACD
ODDS (%)
Bullish Trend 2 days ago
81%
Bearish Trend 2 days ago
86%
TrendWeek
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
TrendMonth
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 2 days ago
90%
Advances
ODDS (%)
Bullish Trend 12 days ago
78%
Bullish Trend about 1 month ago
84%
Declines
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 5 days ago
90%
BollingerBands
ODDS (%)
Bearish Trend 2 days ago
81%
Bearish Trend 2 days ago
90%
Aroon
ODDS (%)
Bearish Trend 2 days ago
90%
Bearish Trend 6 days ago
90%
View a ticker or compare two or three
Ad is loading...
HEPA
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
JAGX
Daily Signalchanged days ago
Gain/Loss if shorted
Show more...
Interesting Tickers
1D
1W
1M
1Q
6M
1Y
5Y
1 Day
STOCK / NAMEPrice $Chg $Chg %
GME22.732.16
+10.50%
GameStop Corp
BTC.X69907.7600001978.460900
+2.91%
Bitcoin cryptocurrency
AAPL233.401.99
+0.86%
Apple
SPY580.831.79
+0.31%
SPDR® S&P 500® ETF Trust
TSLA262.51-6.68
-2.48%
Tesla

HEPA and

Correlation & Price change

A.I.dvisor indicates that over the last year, HEPA has been loosely correlated with AVIR. These tickers have moved in lockstep 45% of the time. This A.I.-generated data suggests there is some statistical probability that if HEPA jumps, then AVIR could also see price increases.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To HEPA
1D Price
Change %
HEPA100%
-5.44%
AVIR - HEPA
45%
Loosely correlated
+2.39%
PMCB - HEPA
39%
Loosely correlated
-0.56%
OTLK - HEPA
34%
Loosely correlated
+5.88%
ATAI - HEPA
34%
Loosely correlated
+7.02%
KRYS - HEPA
33%
Poorly correlated
+0.79%
More

JAGX and

Correlation & Price change

A.I.dvisor tells us that JAGX and HEPA have been poorly correlated (+29% of the time) for the last year. This A.I.-generated data suggests there is low statistical probability that JAGX and HEPA's prices will move in lockstep.

1D
1W
1M
1Q
6M
1Y
5Y
Ticker /
NAME
Correlation
To JAGX
1D Price
Change %
JAGX100%
+1.80%
HEPA - JAGX
29%
Poorly correlated
-5.44%
VXRT - JAGX
28%
Poorly correlated
+1.43%
DVHGF - JAGX
27%
Poorly correlated
N/A
AFMD - JAGX
26%
Poorly correlated
+1.35%
SNPX - JAGX
26%
Poorly correlated
+4.51%
More